Malcolm A. Smith

34.5k total citations · 4 hit papers
292 papers, 12.7k citations indexed

About

Malcolm A. Smith is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Malcolm A. Smith has authored 292 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Molecular Biology, 78 papers in Oncology and 75 papers in Neurology. Recurrent topics in Malcolm A. Smith's work include Neuroblastoma Research and Treatments (72 papers), Acute Lymphoblastic Leukemia research (58 papers) and Cancer therapeutics and mechanisms (29 papers). Malcolm A. Smith is often cited by papers focused on Neuroblastoma Research and Treatments (72 papers), Acute Lymphoblastic Leukemia research (58 papers) and Cancer therapeutics and mechanisms (29 papers). Malcolm A. Smith collaborates with scholars based in United States, Australia and United Kingdom. Malcolm A. Smith's co-authors include Peter J. Houghton, C. Patrick Reynolds, John M. Maris, Richard B. Lock, E. Anders Kolb, Richard Görlick, Gregory H. Reaman, Stephen T. Keir, Christopher L. Morton and Hernán Carol and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Malcolm A. Smith

280 papers receiving 12.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

2010 1.2k citations Alice L. Yu, Andrew L. Gilman et al. profile →
Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

2010 744 citations Malcolm A. Smith, Gregory H. Reaman et al. profile →
Study design and cohort characteristics of the childhood cancer survivor study: A multi‐institutional collaborative project

2002 553 citations Malcolm A. Smith et al. profile →
Declining childhood and adolescent cancer mortality

2014 363 citations Malcolm A. Smith, Gregory H. Reaman et al. profile →

Peers

Countries citing papers authored by Malcolm A. Smith

Since Specialization

Citations

This map shows the geographic impact of Malcolm A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm A. Smith more than expected).

Fields of papers citing papers by Malcolm A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm A. Smith. The network helps show where Malcolm A. Smith may publish in the future.

Co-authorship network of co-authors of Malcolm A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm A. Smith. A scholar is included among the top collaborators of Malcolm A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm A. Smith. Malcolm A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma 2022 ·Cancer Research Communications ·Kateryna Krytska, (unknown), Jennifer Pogoriler, Daniel Martínez, Komal S. Rathi, Alvin Farrel, Esther R. Berko, (unknown), (unknown), Nathan M. Kendsersky, Stephen W. Erickson, Beverly A. Teicher, Kumiko Isse, Laura R. Saunders, Malcolm A. Smith, John M. Maris, Yaël P. Mossé	5
2	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 2021 ·Clinical Cancer Research ·Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm A. Smith, Barry L. Shulkin, Marguerite T. Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park, Paul M. Sondel	132
3	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer 2021 ·Molecular Cancer Therapeutics ·Gilles Vassal, Peter J. Houghton, Stefan M. Pfister, Malcolm A. Smith, Huib N. Caron, Xiao‐Nan Li, David J. Shields, Olaf Witt, Jan J. Molenaar, Sara Colombetti, Julia Schüler, (unknown)	16
4	ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium 2020 ·Molecular Cancer Therapeutics ·Pooja Hingorani, Michael Roth, (unknown), Wendong Zhang, Jonathan Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory J. Gatto, Malcolm A. Smith, E. Anders Kolb, Richard Görlick	23
5	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts 2020 ·Clinical Cancer Research ·Andrew J. Robles, Raushan T. Kurmasheva, Abhik Bandyopadhyay, Doris A. Phelps, Stephen W. Erickson, Zhao Lai, Dias Kurmashev, Yidong Chen, Malcolm A. Smith, Peter J. Houghton	11
6	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL 2017 ·Clinical Cancer Research ·(unknown), Jennifer Richmond, Kathryn Evans, Hernán Carol, Duohui Jing, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	17
7	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant 2016 ·Cancer Research ·Jennifer Richmond, Alissa K. Robbins, Kathryn Evans, Dominik Beck, Raushan T. Kurmasheva, Catherine A. Billups, Hernán Carol, Susan L. Heatley, Rosemary Sutton, Glenn M. Marshall, Deborah L. White, John E. Pimanda, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	18
8	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis 2016 ·Cancer Research ·Brendan Murphy, (unknown), John M. Maris, E. Anders Kolb, Richard Görlick, C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, Raushan T. Kurmasheva, Igor Dvorchik, Jianrong Wu, Catherine A. Billups, (unknown), Malcolm A. Smith, Richard B. Lock, Peter J. Houghton	40
9	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse 2016 ·Cancer Research ·Jason E. Farrar, (unknown), Rhonda E. Ries, Daniel Wai, Oliver Hampton, Lisa R. Treviño, Todd A. Alonzo, Jaime M. Guidry Auvil, Tanja M. Davidsen, Patee Gesuwan, Leandro C. Hermida, Donna M. Muzny, Ninad Dewal, Navin Rustagi, Lora Lewis, Alan S. Gamis, David A. Wheeler, Malcolm A. Smith, Daniela S. Gerhard, Soheil Meshinchi	104
10	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia 2016 ·Cancer Research ·Sibasish Dolai, (unknown), Alissa K. Robbins, Ling Zhong, Susan L. Heatley, Tiffaney L. Vincent, Falko Hochgräfe, Rosemary Sutton, Raushan T. Kurmasheva, Tamás Révész, Deborah L. White, Peter J. Houghton, Malcolm A. Smith, David T. Teachey, Roger J. Daly, Mark J. Raftery, Richard B. Lock	12
11	Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia 2015 ·Clinical Cancer Research ·Jennifer Richmond, Hernán Carol, Kathryn Evans, (unknown), (unknown), Alissa K. Robbins, Claus Meyer, Nicola C. Venn, Rolf Marschalek, Michelle J. Henderson, Rosemary Sutton, Raushan T. Kurmasheva, Ursula R. Kees, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	41
12	Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor 2015 ·Molecular Cancer Research ·Amélie Forest, (unknown), Dale L. Ludwig, (unknown), Ying Wang, (unknown), Gregory P. Donoho, (unknown), Heinz H. Fiebig, Marie Prewett, David Surguladze, (unknown), Peter J. Houghton, Malcolm A. Smith, Ruslan D. Novosiadly	27
13	Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia 2014 ·Molecular Cancer Therapeutics ·Santi Suryani, (unknown), Richard C. Harvey, (unknown), Hernán Carol, I‐Ming Chen, Kathryn Evans, (unknown), Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	43
14	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program 2014 ·Clinical Cancer Research ·Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Görlick, Hernán Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton	90
15	The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia 2013 ·Clinical Cancer Research ·Hernán Carol, Barbara Szymanska, Kathryn Evans, Ingrid Boehm, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock	57
16	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program 2010 ·Molecular Cancer Therapeutics ·Peter J. Houghton, Christopher L. Morton, Richard Görlick, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, (unknown), Amy Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith	79
17	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia 2010 ·Blood ·Richard C. Harvey, Charles G. Mullighan, I‐Ming Chen, Walker Wharton, Fady M. Mikhail, Andrew J. Carroll, Huining Kang, Wei Liu, Kevin K. Dobbin, Malcolm A. Smith, William L. Carroll, Meenakshi Devidas, W. Paul Bowman, Bruce M. Camitta, Gregory H. Reaman, Stephen P. Hunger, James R. Downing, Cheryl L. Willman	395
18	microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies 2009 ·Clinical Cancer Research ·Jun S. Wei, Peter A. Johansson, Qingrong Chen, Young Song, Steffen Durinck, Xinyu Wen, Adam Cheuk, Malcolm A. Smith, Peter J. Houghton, Christopher L. Morton, Javed Khan	44
19	Molecular Characterization of the Pediatric Preclinical Testing Panel 2008 ·Clinical Cancer Research ·Geoffrey Neale, Xiaoping Su, Christopher L. Morton, Doris A. Phelps, Richard Görlick, Richard B. Lock, C. Patrick Reynolds, John M. Maris, Henry S. Friedman, Jeffrey S. Dome, Joseph D. Khoury, Timothy J. Triche, Robert C. Seeger, Richard J. Gilbertson, Javed Khan, Malcolm A. Smith, Peter J. Houghton	95
20	Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis 2007 ·Cancer Research ·Craig C. Whiteford, Sven Bilke, Braden T. Greer, Qingrong Chen, Till Braunschweig, (unknown), Jun S. Wei, Malcolm A. Smith, Peter J. Houghton, Christopher L. Morton, C. Patrick Reynolds, Richard B. Lock, Richard Görlick, Chand Khanna, Carol J. Thiele, Mikiko Takikita, Daniel Catchpoole, Stephen M. Hewitt, Javed Khan	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact